Bio-Plex Multiplex Assays Video

Bio-Plex Pro SARS-CoV-2 Neutralization Antibody Assays provide reliably measure neutralizing antibodies in less than 3 hours. Watch our webinar to learn more.

The Bio-Plex Assay development process is designed to produce high performance multiplex assays. We prioritize sensitivity, broad dynamic range, reproducibility, and shorter incubation times to get you meaningful results faster. Watch this video to learn more about our SMARTS approach to assay development.

Biomarker screening can sometimes be like working in a black box. While traditional research tools focus on one protein at a time, Bio-Rad’s new Bio-Plex Pro™ Mouse Chemokine Panel can simultaneously interrogate 33 chemokines and cytokines in a single well. See how you can get more answers with this panel.

A “device time-out” message on the Bio-Plex^® 200 System occurs when the instrument’s needle or probe cannot move correctly. Watch this video for several troubleshooting steps to try when this message occurs.

The high-throughput fluidics (HTF) alarm on the Bio-Plex^® 200 System indicates a problem with the instrument’s sheath fluid delivery system. See the actions needed to quickly resolve potential issues with this system and get back to your research!

During calibration of your Bio-Plex^® 200 System, you may receive a “failed to pressurize message.” In this short video, get some easy fixes for the most common issues prompting this message.

Researchers at the Immaculate Dermopathic Institute (IDI-IRCCS, Rome) are using Bio-Plex technology in developing new anti-proliferation molecules and markers at the early stages of melanoma pathology. Dr Antonio Facchiano discusses how Bio-Plex has expedited the lab’s research.

Dr Hunseok Lee of Seoul National University explains why it was advantageous for him to use the Bio-Plex system to measure cytokine levels in patients administered with the new cancer vaccine that his laboratory has developed.

Watch how the Bio-Plex® suspension array system has contributed to research findings in Dr Francis Spinale and Dr Steven Kornblau’s laboratories that have the potential to impact screening and treatment of disease.